Alliance Pharma Share Discussion Threads

[pyemckay] 14/1/2014 23:33

how much sales do ashton parsons draw in? used that with my daughter when she was a baby.

[cisk] 14/1/2014 20:14

pye - while I'm a fan of APH, your comments have certainly given me pause to remember why I invested in this company in the first place.

You're right - it's not a company that will suddenly grow at 50% in a year - but then it's not one that will do the opposite either.

It has (relatively) stable earnings, with the potential to enhance sales of established products through sales and promotional effort, that were often overlooked by previous owners.

If APH can assemble related products and push these through a niche sale force - then this would become a very profitable niche.

For example - selling parsons to infants, then lypsil to children etc - you could see, how over time, these would become complimentary and could do well.

I think it's priced right currently, with a p/e around 10-11 and yield of 2.6% (but growing).

Add in cash generation, a large stake held by John Dawson & family and, for me, it sits well in a place in my portfolio for stable businesses with potential upside.

For me, the biggest disappointment, was the delay in getting ashton & parsons moving again - from anecdotal evidence I believe this product could do so much better. I remember a new line being commissioned in Q4 2013 - so not sure what the delay is.

The toxicology slowdown has already been well flagged by the company so should not be a surprise to any who follow the company.

[pyemckay] 14/1/2014 19:03

read the first page of the report marazin.

turnover flat for 5 years
profits trending down.

whats to like here?

[pyemckay] 14/1/2014 19:00

hxxp://www.stockmarketwire.com/article/4738771/FLASH-Investec-cuts-Alliance-Pharma-to-sell-from-reduce-target-cut-from-33p-to-30p.html

[pyemckay] 14/1/2014 18:58

downgraded to 30p today which is harsh. Its reasonably priced now as its a very low growth share. 32p might tempt me.

[mazarin] 14/1/2014 18:49

Alliance Pharma has negotiated to acquire the rights to thyroid product Irenat from pharma giant Bayer, representing its first acquisition in Germany. Last year sales of Irenat were €800,000 giving a gross margin of €500,000, and while Bayer were unwilling to reveal the price paid by Alliance, broker finnCap estimates the price tag to be around the €1-1.5mln mark. Today's market response, is perhaps not quite the one APH would have wished.

[mazarin] 13/1/2014 10:35

A comprehensive research report issued 5th Dec13 for APH by Hardman & Co on the Company is, IMO worth the read, if you have a little time to spare. It makes some interesting and informative reading.

[bamboo2] 13/1/2014 10:17

Trading Update put back to tomorrow.

[mazarin] 09/1/2014 23:46

Fully understand, but try to keep Headers up to date when I still hold an interest

[bamboo2] 09/1/2014 17:52

lol, so used to headers being out of date I didn't look.

[mazarin] 09/1/2014 17:21

Trading Update date is in the header...! 13th Jan 2014

[bamboo2] 09/1/2014 17:16

..that looks to be the about 50% retraction. Probably start to see buying around this level. Is there a trading statement due?

[bamboo2] 07/1/2014 08:11

Steep rises in the share price often retract about 50% soon after, so this could drop a little further, before buyers come back.

Often a chart will then form a flag or pennant consolidation pattern, before continuing on its way.

edited for clarity

[cisk] 06/1/2014 18:27

PTH, I wouldn't worry, fairly low volume, probably market makers talking the stock down on the back of a fairly sharp rise last month

[petethehippy] 06/1/2014 17:04

What happened today?

[mazarin] 31/12/2013 17:47

Just for the record I see from Alliance Pharma's own Investor page that today's Share Price closed at 41p, as a result of just 2 trades (total volume 50,000) shares. My broker (iii) still has it at 40p, whereas ADVFN seemingly has at 40.5p.

Sooner or later I've no doubt whatever the correct price is, it'll get adjusted. Either way, its been a relatively good end to the year for APH that closed 29% up overall, with a promise of increasing dividends and hopefully more 'value enhancing' acquisitions to follow.

[bamboo2] 30/12/2013 09:37

cheers bert

[norbert colon] 30/12/2013 09:33

Yes confirmed. Check recent RNS's.

[bamboo2] 30/12/2013 09:08

Can anyone confirm that their are no longer any convertibles remaining?

[pimpernel4] 27/12/2013 09:34

A fantastic close to the year for Alliance. All credit to the management for steering the ship through the challenges and ending 2013 with a high visibility brand acquisition which appears to have gone down rather well with the market.

Happy New Year and all the best for 2014 to the company and all holders.

[mazarin] 24/12/2013 13:22

Nice to see a couple of 'clicks' up (to 40p) this morning in time for Christmas...! It'll be even more interesting to see where the 'sp' gets to next Christmas.........!

[cisk] 20/12/2013 17:44

Mazarin, I never left - just been lurking with the occasional post ;-)

Still like APH, don't think the price is overvalued; I know a few perceived the last results as a bit lackluster, but for me they were as expected, and 2014 promises to be a year of consolidation, with a ramp up of Ashton & parsons and Immuncyst coming back on stream (although I suspect it will be H2 before any benefits come through).

Add in a few new acquisitions in the new year and I could see them being 50-60 pence in 12 months' time. Add a rising dividend and I'll be a happy man.

[mazarin] 20/12/2013 16:24

I'm amused to note that Wednesday 'Proactive Investors' quoted finnCap's future target price for APH as '38.5p'. If today's positive movement is anything to go by, may I suggest that finnCap analysts sit down and do some more 'work'.

PS. Cisk - Glad to see you're still 'on board' and reaping the benefits..

[cisk] 20/12/2013 14:28

I'll take boring any day if it buys some shares in a company like APH. Having met John Dawson several times, he's a straight-talking guy who is passionate about his company.

Can only echo the comments from others re: CULS - indeed I asked John Dawson if they would ever issue more to finance a deal - empathic reply was no. The CULS have been a depressant on the stock for a long time, as soon as the price ticked up a few more were converted. Hopefully we'll see the shares north of 40p in the new year.

Re: lypsyl - it's a very well respected brand; I used it as a kid and a quick straw poll of coworkers indicates that many did as well. Maybe an opportunity to build a more youthful brand (after all, APH has Ashton & Parsons as well)?

Regardless, it's a great company which should be relatively immune to a market sell-off, should it occur.